Abstract
To the Editor: We have carefully read the interesting article by Akins et al1 focusing on a pivotal issue in the prevention of atrial fibrillation-related stroke. The authors pooled the data from high-risk (previous stroke/TIA) versus nonhigh-risk (no previous stroke/TIA) patients included in SPORTIF III2 and SPORTIF V3 trials in which the direct thrombin inhibitor ximelagatran was compared with warfarin in the primary and secondary prevention of thromboembolic stroke. The authors concluded stating that ximelagatran was at least as effective as warfarin. In our opinion, some points deserve attention and a deeper examination. Our group recently published nonfunded/nonbiased meta-analytic …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
